J&J expanding vaccine trial to adolescents

Johnson & Johnson will soon start testing its COVID-19 vaccine candidate in U.S. adolescents, the company announced Friday. The company plans to begin testing the vaccine in a small number of 16 and 17 year olds as part of an ongoing Phase 2 trial for adults, gradually expanding the trial to children aged 12-17 after reviewing the initial data.
It is currently enrolling adolescents in Spain and the United Kingdom and expects to start enrolling them soon in the U.S., Netherlands and Canada, followed by Brazil and Argentina.
In February, the U.S. Food and Drug Administration authorized emergency use of the vaccine for individuals 18 and older.
Related News Articles
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…